Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT study of SNAC in healthy males
NCT02911870Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- May 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Part A, SNAC, Part A, placebo and Part B, SNAC, Placebo, Moxifloxacin (3 arms). Primary endpoints: Number of treatment emergent adverse events and Fridericia heart rate corrected QT interval at 12 hours. Started Sep 2016; status: completed.
02
Drugs
salcaprozate sodium
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02911870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911870.